Fortress Biotech, Inc. to Post FY2027 Earnings of ($6.67) Per Share, HC Wainwright Forecasts (NASDAQ:FBIO)

Fortress Biotech, Inc. (NASDAQ:FBIO) – Equities researchers at HC Wainwright issued their FY2027 earnings per share (EPS) estimates for shares of Fortress Biotech in a research note issued to investors on Tuesday, April 9th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will earn ($6.67) per share for the year. The consensus estimate for Fortress Biotech’s current full-year earnings is ($5.12) per share.

Several other analysts also recently commented on FBIO. Roth Mkm started coverage on Fortress Biotech in a research note on Friday, March 15th. They set a “buy” rating and a $10.00 price objective on the stock. StockNews.com downgraded Fortress Biotech from a “hold” rating to a “sell” rating in a research note on Friday. Finally, Alliance Global Partners started coverage on Fortress Biotech in a research note on Tuesday, March 19th. They set a “buy” rating and a $5.00 price objective on the stock.

Fortress Biotech Stock Performance

FBIO stock opened at $1.82 on Thursday. The business’s fifty day moving average is $1.93 and its 200-day moving average is $2.37. The company has a quick ratio of 1.26, a current ratio of 1.38 and a debt-to-equity ratio of 38.42. The company has a market cap of $35.02 million, a P/E ratio of -0.22 and a beta of 1.51. Fortress Biotech has a twelve month low of $1.24 and a twelve month high of $12.75.

Institutional Trading of Fortress Biotech

Several hedge funds have recently added to or reduced their stakes in FBIO. Advisor Group Holdings Inc. raised its stake in shares of Fortress Biotech by 113.0% in the 1st quarter. Advisor Group Holdings Inc. now owns 20,020 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 10,620 shares during the period. Two Sigma Securities LLC acquired a new stake in shares of Fortress Biotech in the 1st quarter valued at about $30,000. Wells Fargo & Company MN raised its stake in shares of Fortress Biotech by 49.3% in the 4th quarter. Wells Fargo & Company MN now owns 47,441 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 15,657 shares during the period. BNP Paribas Arbitrage SA raised its stake in shares of Fortress Biotech by 495.0% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 39,636 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 32,974 shares during the period. Finally, Envestnet Asset Management Inc. acquired a new stake in shares of Fortress Biotech in the 1st quarter valued at about $33,000. Institutional investors and hedge funds own 96.51% of the company’s stock.

About Fortress Biotech

Fortress Biotech, Inc, a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne.